Interview with Keith Martin, CEO, Apitope
Apitope’s research and success is based on its High Speed Technology Platform that uses soluble peptides as vehicles to regulate immune responses in patients. What is the history behind this…
Address: Bristol & Bath Science Park
Dirac Crescent
Emersons Green
Bristol
BS16 7FR
United Kingdom
Tel: +44 (0)117 370 7720
Apitope is a privately owned European biotech company developing antigen specific therapeutic peptides for the treatment of allergy and autoimmune diseases, including multiple sclerosis, Graves’ disease, Uveitis, and others.
Autoimmune disease arises from our own immune system responding incorrectly to the proteins and complex tissues that make up our body. For example, multiple sclerosis is caused by immune cells attacking the myelin sheath that insulates the neurons within nervous system including the brain and spinal cord.
Our research team is currently developing peptide based therapeutics designed to selectively suppress this aberrant interaction between immune cell and protein antigen, reinstating the body’s natural immune tolerance to the body’s own proteins.
This approach is founded on peer reviewed research demonstrating that treatment with a soluble, synthetic peptide derived from a known antigenic protein (such as myelin basic protein; a constituent of myelin) can prevent the immune system from responding to that protein as a threat.
In order to induce this process of immune-tolerance we must first identify the region within an antigen that the immune system recognises as a threat during an autoimmune disease. This region is referred to as an epitope.
However, Apitope has shown that in order for an epitope to effectively suppress disease it must behave as an Apitope® – Antigen Processing Independent epiTOPE. Our patented discovery platform enables us to efficiently identify and design these unique peptide therapeutics.
We aim to become the partner of choice for companies developing disease modifying therapies for autoimmune diseases and allergies.
Driving us towards this goal, Apitope has an highly experienced senior management team, each with a proven track record in the translation of novel therapeutics from bench to bedside.
Apitope’s most advanced product candidate, ATX-MS-1467, is undergoing Phase I trials in patients with multiple sclerosis. Our clinical development team is working in partnership with Merck-Serono, a leading company in the development and marketing of MS therapies, to move our product ahead as quickly and effectively as possible.
The company’s lead product candidate is under investigation for the potential treatment of multiple sclerosis and is currently in Phase I clinical development. It is partnered with Merck-Serono (a division of Merck KGaA, Darmstadt, Germany), one of the leading companies in the development and marketing of MS therapies.
Apitope’s research and success is based on its High Speed Technology Platform that uses soluble peptides as vehicles to regulate immune responses in patients. What is the history behind this…
The signing of an agreement on the terms of a future trade relationship between Japan and the UK has been welcomed by the UK pharma industry, which counts Japan as…
US Merck (MSD globally) is following through on a 2017 commitment to invest in a new early research hub in central London, with plans to open the ‘London Discovery Research…
Jameel Zayed of Leyton, the UK’s leading innovation funding consultancy, highlights the British pharmaceutical industry’s rapid response to COVID-19 and the three ways in which the sector is driving national…
Below we highlight some recent developments in pharma and healthcare in the UK, including drug shortages in British intensive care units (ICUs), COVID-19 drug trials, biotech deals and market access…
The world’s two leading vaccine producers, GSK of the UK and France’s Sanofi, last week announced that they are working together to develop a vaccine for the novel coronavirus (COVID-19);…
With Brexit now confirmed, the UK government has been playing up the country’s scientific credentials. The aim is to cement the UK’s position as one of the world’s top life…
Friday January 31 2020 was officially dubbed “Brexit Day” as the UK finally left the EU, following British Prime Minister Boris Johnson’s sweeping election victory on a promise to “Get…
Although biotech financing in the UK took a hit last year in large part thanks to uncertainty around Brexit, 2019 was still the British industry’s third-best year on record. …
GW Pharmaceuticals reports that sales of its CBD drug Epidiolex more than doubled in the second quarter of 2019, demonstrating that cannabinoid-based medicines can be highly profitable and potentially blazing…
Formed in 2015, listed UK start-up Amryt targets rare diseases with high unmet medical need. With one commercial asset on the market, a strong pipeline of development assets and a…
Hopes have been raised of a cure for AIDS after a patient in London became free of the HIV virus following a bone marrow transplant. Although it is not…
Founded in 1998, GW Pharmaceuticals is a British biopharmaceutical company, best known for being the only company with a license to cultivate cannabis in the UK. True pioneers, they are…
See our Cookie Privacy Policy Here
